Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2016 / Cilt: 9 - Sayı: 3

miRNAs and other non-proteın-coding RNAs in the strategy of diagnosis and treatment of the diseases

Hastalıkların tanı ve tedavi stratejilerinde miRNA ve diğer non- protein-coding RNA'lar

Pages
159–172
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With over 5000 miRNAs discovered in human to date, many of them have already been implicated in common human disorders including cancer, viral and immune-related as well as neurodegenerative diseases. miRNAs have vital potential in becoming the next generation of diagnostics and therapeutics.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recent genome-wide/functional analyses have shown that the human genome is pervasively transcribed and produces several thousands of regulatory non-protein-coding RNAs, including microRNAs, small interfering RNAs, PIWI-interacting RNAs and various classes of long ncRNAs.
📊
Key Findings & Data:They have attracted significant attention from biomedical research communities over the past two decades.
💡
Conclusion & Impact:With over 5000 miRNAs discovered in human to date, many of them have already been implicated in common human disorders including cancer, viral and immune-related as well as neurodegenerative diseases. miRNAs have vital potential in becoming the next generation of diagnostics and therapeutics.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Recent genome-wide/functional analyses have shown that the human genome is pervasively transcribed and produces several thousands of regulatory non-protein-coding RNAs, including microRNAs, small interfering RNAs, PIWI-interacting RNAs and various classes of long ncRNAs. MicroRNAs are a class of short non-coding RNA molecules. They have attracted significant attention from biomedical research communities over the past two decades. Facilitated by high-throughput genomics and bioinformatics in conjunction with traditional molecular biology techniques and animal models, miRNA research is now positioned to make the transition from laboratories to the clinics, delivering profound benefits to public health. MicroRNAs are small, however important regulators of post-transcriptional gene expression that have been linked to various cellular processes. Alterations of miRNAs are associated with the underlying pathology of several diseases. With over 5000 miRNAs discovered in human to date, many of them have already been implicated in common human disorders including cancer, viral and immune-related as well as neurodegenerative diseases. miRNAs have vital potential in becoming the next generation of diagnostics and therapeutics.

Özet

Son yıllarda yapılan tüm genom/fonksiyonel analiz çalışmaları insan genomunun yaygın olarak binlerce düzenleyici non-protein-coding RNA'lar (protein kodlamayan RNA) transkribe ettiğini ortaya koymuştur. Bunlar içerisinde mikro RNA'lar, small interfering RNA'lar, P-element-induced Wimply Testis (PIWI) interacting RNAs'lar ve çeşitli uzun non-protein-coding RNA'lar vardır. Bunlar içerisinde özellikle miRNA'lar son 20 yıldır biyomedikal disiplinlerde tanı ve tedavi stratejisi geliştirilmesinde oldukça geniş bir ilgi odağı haline gelmiştir. MikroRNA'lar kısa nonprotein-coding RNA moleküllerinin bir sınıfıdır. Yüksek kapasiteli genomik ve biyoinformatik tekniklerin geleneksel moleküler biyoloji teknikleri ve deney hayvanı çalışmaları ile bütünleşmesi ile mikroRNA araştırmaları, günümüzde elde edilen ön bulguların laboratuvardan kliniğe ve halk sağlığına aktarılmasında önemli bir yer tutmaktadır. mikroRNA'lar küçük olmalarına rağmen çeşitli hücresel süreçlerle ilişkili olan post-transkripsiyonel gen ekspresyonunun önemli düzenleyicileridir. Bu nedenle mikroRNA'larda meydana gelen alterasyonlar tanımlanan bir dizi hastalığın patolojisi ile ilişkilendirilmiştir. Günümüze kadar, insanda 5000'den fazla miRNA keşfedilmiş ve bunların çoğu kanser, viral hastalıklar, immünite ile ilişkili hastalıklar, nörodejeneratif hastalıklar gibi birçok yaygın insan hastalığı ile ilişkilendirilmiştir. miRNA'ların yeni nesil biyomarker ve terapötik olma yolunda önemli potansiyelleri vardır.

🔖

Cite This Article

SERİN, M. S., KARAARSLAN, Z. Ö. (2022). miRNAs and other non-proteın-coding RNAs in the strategy of diagnosis and treatment of the diseases. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 9 - Sayı: 3, 159–172. https://ajindex.com/articles/580369

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Gan L, X Midie, Z Yi, Z Xia, G Weijian. Focusing on long noncoding RNA dysregulation in gastric cancer. Tumor Biol 2015;36:129-141
  2. Meseure D, Alsibai KD, Nicolas A, Bieche I and Morillon A. Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. BioMed Research International 2015:14 3. J.M. Perkel. Visiting 'noncodarnia'. BioTechniques 2013;54(6):301-304
  3. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. "Non-coding RNAs: regulators of disease." J Pathol 2010;220(2):126-139
  4. Peng Qi, Xiang Du. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Modern Pathology 2013;26:155-165
  5. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010;28(11):570-579
  6. Hrdlickova B, de Almeida RC, Borek Z, Withoff S. "Genetic variation in the noncoding genome: Involvement of micro-RNAs and long non-coding RNAs in disease". Biochim Biophys Acta 2014;1842(10):1910- 1922
  7. Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Bio 2011;12:246-258
  8. Hauptman N, Glavac D. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol 2013;47(4):311-318
  9. Mattick JS ve Makunin IV. Small regulatory RNAs in mammals. Human Molecular Genetics 2005;14(1):121-132
  10. Saydam F, Değirmenci İ, Güneş HV. MikroRNA'lar ve kanser. Dicle Tıp Dergisi 2011;38(1):113-120
  11. Takamizawa, J, Konishi, H, Yanagisawa, K, Tomida, S, Osada, H, Endoh, H, Harano, T, Yatabe, Y, Nagino, M, Nimura, Y. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64(11):3753-3756 13. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med, 2010;363(19):1877
  12. Kim J, Bartel D. Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNAdirected repression. Nat Biotechnol 2009;27(5):472-477
  13. Gloss BS, Dinger ME. The specificity of long noncoding RNA expression, BBA - gene regulatory mechanisms. Biochim Biophys Acta. 2016;1859(1):16-22 16. Hydbring P, Badalian-Very G. "Clinical applications of microRNAs".Version 3. F1000Res. 2013;2:136
  14. Huang Z, Huang D, Ni SJA, Peng ZL, Sheng WQ, Du X. Plasma microRNAs are promising nove